B
Maze Therapeutics, Inc. — Earnings Quality Grade B
MAZE · Healthcare
Generally healthy
Revenue
$0M
2025
Net Income
-$131M
2025
Gross Margin
—
Free Cash Flow
-$113M
01
Screening Summary
10
Passed
2
Watch
0
Failed
—
M-Score
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
✓
A3Revenue vs CFFO
Revenue -100.0%, CFFO -247.4%. Cash follows revenue
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
✓
B2CapEx vs Revenue
CapEx growth -30.8% vs revenue -100.0%. Normal
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
✓
C1CFFO vs Net Income
CFFO/NI = 0.85. Profits backed by cash
!
C2Free Cash Flow
FCF is negative ($-0.1B)
✓
C3Accruals Ratio
Accruals ratio = -4.8%. Low accruals
✓
C4Cash vs Debt
Cash $0.3B covers debt $0.0B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
✓
D2Leverage
Debt/EBITDA = -0.2x. Healthy
✓
D3Soft Asset Growth
Other assets -53.8% vs revenue -100.0%. Normal
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
!
E1Serial Acquirer FCF
FCF after acquisitions negative for 2/3 years
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
7.81
Safe Zone0 Distress1.102.605.0+ Safe
0.8238
Liquidity
-1.2327
Cumulative profit
-0.3598
Operating efficiency
8.4193
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25